Related Experiment Video
Updated: Sep 9, 2025

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
The Association of the 340B Program with Affordable Care Act (ACA) Premiums: A Longitudinal Analysis from 2018 to
Neal Masia1, James D Motyka2, Kimberly Westrich2
1Health Capital Group, LLC and Columbia University, New York, NY, USA.
Abstract:
We tested whether the 340B program impacts Affordable Care Act (ACA) premiums. Data from 2018 to 2022 was used to establish a baseline for silver benchmark premiums and other key measures, including: the number of active 340B sites per 10,000 people in a county (Hospital Site Density, or HSD), ACA benchmark plan premiums for every county, and measures likely to influence insurance premiums including per capita income, unemployment, and hospital market power. We used a multivariate fixed effects regression that included state and year effects, the explanatory variables, and the county-level HSD for each year. The impact of 340B on ACA premiums was illustrated using 2022 data. We estimate that a 1-unit change in 340B HSD was associated with a 1.1% (95% CI 0.73-1.15) change in the benchmark ACA premium. In 2022, the mean county 340B HSD was 1.63, and the mean Silver Benchmark Plan monthly premium was $500. After adjusting for per capita income, hospital concentration index, and other factors, the mean 340B HSD accounted for 1.8% (95% CI: 1.3-2.1) of the average Silver Benchmark Plan monthly premium, or $8.90 (95% CI $6.50-$10.25) per month, implying a cost in additional subsidies of over $106 per year per subsidized ACA enrollee. The results support that the 340B program is associated with a financially meaningful component of ACA premiums.
More Related Videos
05:16Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
Related Concept Videos
Longitudinal Research
Actuarial Approach
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Longitudinal Studies
Cross-Sectional Research
Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Introduction To Survival Analysis
The primary goal of survival analysis is to estimate survival time—the time...